460 completed, 213 recruiting, 166 unknown, 146 terminated. 578 Phase 2, 396 Phase 1, 129 Phase 3, 94 Not applicable, 12 Phase 4.
Follow Small Cell Lung Carcinoma: new trials by email Literature Review of Small Cell Lung Carcinoma trials Research Report on Small Cell Lung Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC Durvalumab 50 MG/1 ML Intravenous Solution, Etoposide Injection, Cisplatin - Extensive-stage Small-cell Lung Cancer | Phase 1 | Suspended | University of Maryland, Baltimore | 50 | 2027-01-30 | 2026-09-14 |
| Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer Lurbinectedin, Osimertinib - Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Misty Shields | 16 | 2027-01-01 | 2026-10-15 |
| Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer Tarlatamab, Durvalumab - Limited Stage Small-Cell Lung Cancer | Phase 3 | Not yet recruiting | PrECOG, LLC. | 430 | 2027-01-01 | 2026-06-09 |
| A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer ZL-1310 in combination with Atezolizumab or Durvalumab, Carboplatin/Etoposide in Combination with Atezolizumab followed by maintenance Atezolizumab with Lurbinectedin, Carboplatin/Etoposide or Cistplatin/Etoposide in Combination with Durvalumab induction followed by Durvalumab maintenance - Extensive-Stage Small Cell Lung Cancer | Phase 3 | Not yet recruiting | Zai Lab (Shanghai) Co., Ltd. | 530 | 2026-12-31 | 2026-08-31 |
| A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation LG00313112 - Ovarian Cancer, Small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | LG Chem | 250 | 2026-12-01 | 2026-08-07 |
| A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC Lurbinectedin, Durvalumab - Extensive-stage Small-cell Lung Cancer | Phase 2 | Recruiting | Jazz Pharmaceuticals | 50 | 2026-11-30 | 2026-09-17 |
| Prospective Multiomic Analysis in Small-Cell Lung Cancer Biospecimen collection - Small Cell Cancer Of The Lung, Small Cell Lung Cancer ( SCLC ) | Recruiting | Ohio State University Comprehensive Cancer Center | 30 | 2026-11-25 | 2026-10-02 | |
| Lurbinectedin Plus Paclitaxel Versus Paclitaxel in Patients With Previously Treated Small Cell Lung Cancer Lurbinectedin, Paclitaxel - Carcinoma, Small Cell Lung | Phase 2 | Not yet recruiting | Yonsei University | 69 | 2026-11-01 | 2026-09-04 |
| A Phase 1 Study of IM-1340 in Participants With Advanced Cancer IM-1340 - Colorectal Cancer, Non-Small Cell Lung Cancer | Phase 1 | Not yet recruiting | Immunome, Inc. | 200 | 2026-11-01 | 2026-10-22 |
| DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers Obrixtamig, ZL-1310, Atezolizumab - Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | Boehringer Ingelheim | 60 | 2026-10-19 | 2026-09-29 |
| Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease Autologous B7-H3 CAR T, Cyclophosphamide, Fludarabine - Recurrent Small Cell Lung Cancer, Extensive-Stage Small Cell Lung Cancer | Phase 1 | Recruiting | National Cancer Institute (NCI) | 40 | 2026-10-16 | 2026-10-21 |
| A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung Cancer QLC5508, QL2107, Tislelizumab - Extensive-stage Small Cell Lung Cancer | Phase 3 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 556 | 2026-10-15 | 2026-09-03 |
| A Phase II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection in Patients With LS-SCLC SHR-7787 Injection, SHR-1316 - Limited-stage Small-cell Lung Cancer | Phase 2 | Recruiting | Shanghai Hengrui Pharmaceutical Co., Ltd. | 120 | 2026-10-07 | 2026-10-19 |
| SCLC Tarlatamab Blood Collection Small-cell Lung Cancer | Not yet recruiting | Duke University | 25 | 2026-10-01 | 2026-08-05 | |
| Effectiveness and Safety of MRG003 (Becotatug Vedotin) in Relapsed SCLC MRG003 (Becotatug Vedotin) - Relapsed Small Cell Lung Cancer (SCLC) | Not applicable | Recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 52 | 2026-10-01 | 2026-10-15 |
| Paclitaxel Polymeric Micelles Plus Ivonescimab in Recurrent or Refractory SCLC Paclitaxel Polymeric Micelles, Ivonescimab - SCLC, Recurrent | Phase 2 | Not yet recruiting | Shaodong Hong | 47 | 2026-10-01 | 2026-09-15 |
| A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35) Obrixtamig, Pumitamig, Carboplatin - Extensive-stage Small Cell Lung Carcinoma, Advanced Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Boehringer Ingelheim | 55 | 2026-10-01 | 2026-10-13 |
| Evaluation of the Value of [68Ga]Ga-PENTIXAFOR PET-CT in Patients With Metastatic Small Cell Lung Cancer (SCLC) [68Ga]Ga-PentixaFor - Small Cell Lung Carcinoma (SCLC) | Early Phase 1 | Not yet recruiting | Institut Cancerologie de l'Ouest | 15 | 2026-09-30 | 2026-06-18 |
| A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC) Alisertib, Paclitaxel - Small Cell Lung Cancer ( SCLC ) | Phase 2 | Recruiting | Puma Biotechnology, Inc. | 50 | 2026-09-17 | 2026-09-30 |
| SMARCA4/2 Inhibitor for POU2F3-Positive SCLC FHD-286 - Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Dana-Farber Cancer Institute | 20 | 2026-09-04 | 2026-04-27 |
Showing 20 of 1198. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (343) · Lung Neoplasms (297) · Breast Neoplasms (104) · Stomach Neoplasms (88) · Ovarian Neoplasms (87) · Neoplasms (79) · Melanoma (75) · Carcinoma, Renal Cell (74) · Colorectal Neoplasms (74) · Pancreatic Neoplasms (73) · Uterine Cervical Neoplasms (70) · Carcinoma, Hepatocellular (67) · Prostatic Neoplasms (64) · Squamous Cell Carcinoma of Head and Neck (64)
Bronchial Neoplasms (1197) · Respiratory Tract Diseases (1196) · Carcinoma, Bronchogenic (1195) · Respiratory Tract Neoplasms (1195) · Neoplasms by Site (1194) · Lung Diseases (1192) · Thoracic Neoplasms (1191) · Neoplasms (1119) · Lung Neoplasms (901) · Neoplasms by Histologic Type (292) · Neoplasms, Glandular and Epithelial (252) · Carcinoma (211) · Urogenital Diseases (193) · Urogenital Neoplasms (190) · Digestive System Diseases (189)
Etoposide (161) · Carboplatin (152) · Cisplatin (108) · Topotecan (77) · atezolizumab (54) · durvalumab (54) · Irinotecan (47) · pembrolizumab (42) · Paclitaxel (37) · Nivolumab (32) · Radiotherapy (32) · PM 01183 (28) · anlotinib (25) · Drug Therapy (24) · Gemcitabine (21)
National Cancer Institute (NCI) (59) · AstraZeneca (20) · AbbVie (18) · Amgen (18) · GlaxoSmithKline (15) · Hoffmann-La Roche (13) · Memorial Sloan Kettering Cancer Center (13) · Shanghai Pulmonary Hospital, Shanghai, China (13) · Alliance for Clinical Trials in Oncology (12) · Bristol-Myers Squibb (12) · Eli Lilly and Company (12) · Case Comprehensive Cancer Center (11) · M.D. Anderson Cancer Center (11) · Novartis Pharmaceuticals (10) · Pfizer (10)
United States (601) · China (311) · Spain (135) · France (115) · South Korea (98) · Canada (92) · United Kingdom (91) · Italy (87) · Germany (86) · Poland (77) · Australia (74) · Japan (74) · Belgium (68) · Netherlands (61) · Taiwan (49)
Anish Thomas, M.D. (6) · Stephen Lam, MD (5) · You Lu, MD (5)
PMID 42820295, PMID 30280641, PMID 39113428, PMID 25490004, PMID 29290251, PMID 31590988, PMID 34405547, PMID 34408488, PMID 35576956, PMID 36184621, PMID 23182663, PMID 32346071, PMID 33285097, PMID 33509647, PMID 33595690, PMID 34589918, PMID 34632876, PMID 36166026, PMID 37230961, PMID 38460751, PMID 38811992, PMID 39615412, PMID 39897044, PMID 42497381, PMID 42580817, PMID 10080612, PMID 10561263, PMID 12056703, PMID 12431965, PMID 12467231, PMID 12704670, PMID 1310103, PMID 14581415, PMID 15013589, PMID 15033677, PMID 15249451, PMID 15480814, PMID 16148284, PMID 16170339, PMID 16226617, PMID 1648142, PMID 16968876, PMID 17008692, PMID 17065590, PMID 17280921, PMID 17285598, PMID 17409859, PMID 17409985, PMID 17513814, PMID 17545536
2023 (17), 2025 (14), 2016 (13), 2017 (11), 2019 (11), U10CA031946 (8), 2015 (6), P30CA043703 (6), 2018 (5), 2014 (4), P30CA015083 (4), P30CA016672 (4), P30CA068485 (4), UM1CA186689 (4), UM1CA186691 (4)